Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb Talks Activist Role For FDA In Curbing REMS Abuse

Executive Summary

US FDA commissioner says he would be happy to work with Congress on a legislative solution on the issue, but emphasized his priority is for the agency to develop a system itself to discourage REMS abuse.

Advertisement

Related Content

US FDA To Publish Own Datasets In Latest Signal Of Enhanced Transparency
Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes
Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
Can US FDA Save Pharma From Price Controls?
Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS120914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel